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OBJECTIVES: To estimate the health and economic value of participation in digital 
lifestyle intervention program for people with prediabetes METHODS: The study 
investigated ‘Prevent’ program which is modeled after CDC’s Diabetes Prevention 
Program. The core phase of this digital program consisted of 16 weekly lessons, fol-
lowed by periodic follow-up to reinforce lesson content and provide encouragement. 
The analysis sample included 2,371 Prevent participants who were overweight or 
obese and have prediabetes. Participants’ weight at or before 26 weeks was stud-
ied to calculate weight change. A Markov-based microsimulation model simulated 
onset of obesity and diabetes comorbidities annually over 10 years among partici-
pants under two scenarios (1) weight loss and A1c improvements achieved through 
Prevent, and (2) natural history of disease in the absence of Prevent. A second popu-
lation that met USPSTF’s recommendation for intensive behavioral counselling was 
also evaluated following the same process to estimate the benefits of ‘Prevent’ in 
different populations. RESULTS: Participants with prediabetes experienced aver-
age weight loss of 5.13%. Prevent was associated with a 28% reduction in diabetes 
onset over 3 years and 30% over 5 years. Cumulative over 3 and 5 years, the present 
value of reduced medical expenditures averaged $1,310 and $2,870, respectively. 
Comparing medical savings to program costs, the break-even point was two years. 
The simulated return on investment (ROI) was $860 after 3 years, $2,420 after 5 
years, and $8,770 after 10 years. In the USPSTF population, the model projected 
reduction in disease onset similar to that in the prediabetes population. The ROI 
was $950, $2,370 and $7,500, for 3, 5, and 10 years, respectively. CONCLUSIONS: 
Intensive lifestyle intervention is recommended by the U.S. Preventive Services 
Task Force as the first-line treatment for prediabetes, and internet-based programs 
like Prevent appear to provide both substantial health benefits to participants and 
high return on investment.
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OBJECTIVES: The observational, non-interventional EDGE study showed that vilda-
gliptin is effective in patients with type 2 diabetes mellitus who have suboptimal 
glycemic control on metformin (MET) monotherapy in the real-world setting, con-
firming the results of previous randomized clinical trials (RCTs). Cost-effectiveness 
evaluations are typically based on RCT data, which offer high internal validity and 
are the gold standard in evaluating efficacy and short-term safety. Nevertheless, 
they lack external validity and generalizability and there is a growing trend towards 
the complementary use of real-world data. Consequently, we sought to perform a 
health economic evaluation of the EDGE study using an established diabetes out-
comes model. METHODS: The IMS Core Diabetes Model (CDM), a recently validated 
diabetes model, was used to evaluate the costs and outcomes of MET+vildagliptin 
(M+V) compared to MET+sulfonylurea (M+S), based on data derived from the EDGE 
study worldwide. M+V was associated with HbA1c and BMI changes of -1.19% and 
0.199 kg/m2, respectively. Corresponding data for M+S were -0.99% and 0.707 kg/m2, 
respectively. Published network meta-analysis data were used to populate the CDM 
with hypoglycemia rates. The model was run over a lifetime, with costs ($US) and 
benefits discounted at 3.0%. RESULTS: Predicted quality-adjusted life expectancy 
(QALE) was 11.14 and 11.07 in patients treated with M+V and M+S, respectively. 
Total direct costs were estimated at $US 90,788 and $US 85,692 for patients treated 
with M+V and M+S, respectively. Incremental differences between M+V and M+S 
were 0.07 for QALE and $US 5,096 for total costs, yielding an incremental cost-
effectiveness ratio (ICER) of $US 72,800. CONCLUSIONS: In the real-world setting, 
compared to sulfonylureas, vildagliptin was estimated to be cost effective using US 
ICER thresholds. These data further highlight the potential role of real-world data 
in assessing health economic value.
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OBJECTIVES: Diabetes mellitus (DM) is a chronic disease considered a worldwide 
public health problem. DM can result in harm to the patient in the aspects clinical, 
social, economic and quality of life, given its potential of morbidity and mortality 
DM (SBD, 2003). Expenditures for financing costly dispensing drugs have shown 
continuous growth trend in the Brazilian National Health Service (SUS). This creates 
the need for rationalization and optimization of growing financial contributions of 
resources for health. The purpose of this study was to evaluate the cost-effective-
ness of Glargine - insulin analogue versus NPH - insulin in the treatment of diabetes 
mellitus type I and II. METHODS: We developed a decision model using Markov 
method to perform the cost-effectiveness of Glargine and NPH in the treatment 
of diabetes mellitus type I and II. Calculations were performed for a time horizon 
of 10 to 20 years in annual cycles. The perspective is that of the SUS. Additionally 
analysis Cost-utility and sensitivity were performed. RESULTS: In 20 years (with 5% 
discount), the effectiveness was equal (as in 10 years) between Glargine and NPH 
insulin presenting 7.62 Avg. The total cost to NPH insulin was U$9,114.95 and the 
total cost of insulin Glargine was U$21,128.49 In 20 years (with 5% discount), the 
utility was similar (as in 10 years) between Glargine and NPH insulin presenting 
on US health-care, both directly and through substantially increased risks of micro- 
and macrovascular complications over time. The goal of this study was to estimate 
diabetes-related clinical and economic outcomes following a myocardial infarction 
(MI) or stroke. The impacts of experiencing an MI or stroke on five-year mortal-
ity rates and life expectancy were estimated using National Health and Nutrition 
Examination Survey data. METHODS: A Monte Carlo microsimulation was devel-
oped to estimate the number of complications, mortality, and diabetes-related medi-
cal costs for T2DM patients. The simulation uses T2DM comorbidities from the CDC 
diabetes cost-effectiveness group and risk equations from the United Kingdom 
Prospective Diabetes Study (UKPDS 82). Five-year mortality rate and medical and 
pharmacy costs were estimated for a cohort of 100,000 patients. Cohorts were simu-
lated for five years and projected over a lifetime with and without an initial MI or 
stroke event for both genders and different age groups. One-way sensitivity analyses 
including years since diagnosis, baseline HbA1c, blood pressure, cholesterol, and 
smoking were performed separately for MI and stroke. RESULTS: A 60-year-old male 
patient with a 7.5% baseline HbA1c was estimated to have a mortality rate of 0.15 
over five years and to incur $22,096 without an initial MI or stroke. The mortality and 
cost increased to 0.44 and $69,286 after an initial MI and 0.51 and $73,297 after an 
initial stroke. The patient’s life expectancy decreased from 14.8 years to 7.9 and 6.6 
years after an initial MI and stroke, respectively. CONCLUSIONS: Diabetes-related 
vascular complications significantly decrease life expectancy and increase the eco-
nomic burden of T2DM. Preemptive actions and treatments to reduce MI and stroke 
risk in T2DM patients can be cost-justified.
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OBJECTIVES: The use of ultrasonic devices (UD) in thyroidectomy may have sig-
nificant economic impact due to improved efficiency and benefits of clinical out-
comes without increasing rates of surgical complications. To fully characterize the 
potential economic benefit of UD in thyroidectomy, the objective of this study was 
to develop a provider budget impact model to quantify potential cost savings over 
conventional surgical techniques. METHODS: A budget impact model was devel-
oped in the perspective of a US hospital, comparing the use of UD with conventional 
techniques in patients undergoing thyroidectomy. Clinical parameters were derived 
from published literature, including a meta-analysis of 26 studies, and focused on 
the differences between ultrasonic and conventional surgeries across four areas: 1) 
operating time, 2) blood loss, 3) duration of recovery time, and 4) risks of other com-
plications. Costs of care were obtained from published commercial and Medicare 
fee schedules, and other costs and risks relating to thyroidectomy were obtained 
from published literature. RESULTS: UD showed clinical and economic advantages 
compared to conventional surgery, with notable reductions of operating time and 
blood loss by 29% and 20%, respectively. Reductions were also seen in risk of surgi-
cal site infection and anesthesia utilization due to reduction in operating time, 
with the possibility of reducing other surgical side effects associated with operat-
ing time such as venous thromboembolism. Total cost savings were estimated at 
approximately $1,501 per patient, with the higher up-front cost of the UD offset 
by the aforementioned savings. CONCLUSIONS: The clinical benefits of UD can 
be translated into economic benefits for providers in the US. Further studies are 
needed to assess the impact of those benefits on clinical practice, especially tak-
ing into account the practical consequences of reduced operating time, including 
potential shift in setting from inpatient to outpatient care and possible increases 
in the rate of procedures performed.
PDB44
healTh Care resourCe uTilizaTion anD CosTs among DiaBeTes 
PaTienTs resiDing in long-Term Care faCiliTies
Huang A.1, Shrestha S.1, Baser O.2, Yuce H.3, Wang L.1
1STATinMED Research, Plano, TX, USA, 2STATinMED Research, The University of Michigan, MEF 
University, Ann Arbor, MI, USA, 3City University of New York & STATinMED Research, New York, 
NY, USA
OBJECTIVES: To evaluate health care resource utilization and costs among diabetes 
patients residing in long-term care facilities. METHODS: Patients diagnosed with 
diabetes (International Classification of Diseases, 9th Revision, Clinical Modification 
diagnosis codes 250.x0, 250.x2) were identified using the Long-Term Care Minimum 
Data Set (MDS) linked to 5% Medicare data from 01JAN2009 through 31DEC2010. The 
initial diagnosis date was designated as the index date. A comparison cohort was 
created for patients without diabetes, using 1:1 propensity score matching (PSM) 
to control for age, region, gender and baseline Charlson Comorbidity Index score. 
The index date for the comparison cohort was randomly chosen to reduce selec-
tion bias. Patients in both cohorts were required to be age ≥ 65 years, have at least 
two consecutive quarterly assessments documented in MDS data 6 months prior 
to the index date and have continuous medical and pharmacy benefits for 1-year 
pre- and post-index date. Health care resource utilization and costs were compared 
between the diabetes and comparison cohorts. RESULTS: After applying PSM, 783 
patients were included in each cohort, and baseline characteristics were balanced. 
Diabetes patients had a higher percentage of inpatient (31.29% vs. 22.73%, p= 0.0001), 
skilled nursing facility (SNF, 31.55% vs. 22.73%, p< 0.001), durable medical equip-
ment (27.46% vs. 16.48%, p< 0.0001) and pharmacy visit claims (93.10% vs. 88.76%, 
p= 0.0028) compared to those without diabetes. Patients in the diabetes cohort also 
incurred significantly higher inpatient ($5,801 vs. $3,071, p< 0.0001), SNF ($5,532 vs. 
$3,244, p< 0.0001), carrier claim ($3,118 vs. $2,437, p= 0.0002) and pharmacy visit costs 
($5,040 vs. $4,275, p= 0.0005) than those in the comparison cohort. CONCLUSIONS: 
Patients diagnosed with diabetes had significantly higher health care resource uti-
lization and costs than those without diabetes.
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mg, resulting in ~25% greater 24-hour urinary glucose excretion. In addition, CANA 
300 mg may transiently block intestinal SGLT1, delaying glucose absorption and 
reducing postprandial glucose. METHODS: The IMS CORE Diabetes Model was used 
to evaluate the cost-effectiveness of CANA 100 and 300 mg versus DAPA 10 mg using 
Spanish-specific utilities and cost data. Direct costs were reported in euros and an 
annual discount rate of 3% was applied to costs and effects. The time horizon used 
for the economic evaluation was 40 years to reflect the chronic nature of the disease. 
A randomised, controlled trial of CANA in dual therapy and an NMA were sourced for 
initial patient characteristics and treatment effects. Results were compared with the 
willingness-to-pay (WTP) threshold reported for Spain (€ 30,000/QALY). RESULTS: 
CANA 100 mg dominated DAPA in dual therapy, with 0.061 quality-adjusted life years 
(QALYs) gained. CANA 300 mg was cost-effective compared to DAPA 10 mg in dual 
therapy with a cost-effectiveness ratio below the WTP threshold in Spain; QALYs 
gained were 0.084. CONCLUSIONS: These results suggest that adding CANA 100 or 
300 mg instead of DAPA 10 mg in patients inadequately controlled on metformin 
would result in more efficient use of healthcare resources in the Spanish setting.
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OBJECTIVES: Proper glycemic control reduces the frequency of microvascular and 
macrovascular complications in type 2 diabetes. Many patients require more than 
one medication to reach goal glycated hemoglobin (A1c) levels. The objective of 
this study was to assess the cost-effectiveness of dapagliflozin versus the dipepti-
dyl pepdtidase 4-inhibitors in regards to cost per unit of A1c lowered. METHODS: 
Data for clinical outcomes were abstracted from a meta-analysis comparing the 
effectiveness of oral diabetes medications added to metformin for type 2 diabetic 
patients failing to achieve goal Alc levels with metformin alone. All comparisons in 
the meta-analysis were for a 52 week period. A random effects regression model was 
utilized to compare dapagliflozin to dipeptidyl peptidase 4-inhibitors in their ability 
to lower glycemic levels after adjusting for baseline Alc and additional covariates. 
The costs for the antidiabetic agents were based on published wholesale acquisition 
costs data for 2014. An incremental cost effectiveness ratio (ICER) was calculated 
to determine cost per additional percentage point for lowering the A1c from the 
health payer perspective. RESULTS: Dapagliflozin was more effective than dipepti-
dyl pepdtidase 4-inhibitors in lowering A1c levels and was associated and additional 
0.07% lowering of the A1c level after adjusting for covariates. Dapagliflozin was more 
expensive at an annual cost of $3,470.40 while dipeptidyl pepdtidase 4-inhibitors 
had an annual costs of $3,405.60. The resulting ICER indicated that there was a cost 
$926 for each additional percentage point that the Alc was lowered by using dapagli-
flozin. CONCLUSIONS: Dapagliflozin was more effective than dipeptidyl pepdtidase 
4-inhibitors in lowering A1c levels, yet it was also more expensive. Decision makers 
trying to decide whether or not to use these medications must be prepared to decide 
if the additional benefit is worth the cost.
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OBJECTIVES: To evaluate the CE ratio of empagliflozin 25mg compared to sitagliptin 
100mg when added to MET in patients with T2DM. METHODS: A discrete event simu-
lation CE model was developed to assess the life years (LY) gained and the treatment 
related costs associated with the studied alternatives in a 10-year horizon. Relevant 
clinical outcomes identified where efficacy (HbA1c, systolic blood pressure and weight 
reductions), safety (severe and non-severe hypoglycemia episodes, urinary and geni-
tal infections) and treatment-related complications including discontinuation. The 
results of a Network-Meta-Analysis where taken as efficacy and safety inputs of the 
model. Public institutional direct medical costs (2014 purchases and price tabulators) 
where retrieved to adopt the national health system perspective. A probabilistic sen-
sitivity analysis was performed to endorse the results. RESULTS: In the 10-year time 
horizon adopted, and after running 5000 simulations per treatment arm, sitaglitpin 
100mg was estimated to have the highest cost of treatment with $179,124.75 MX 
against $175,842.69 MX reported by empagliflozin 25mg. A small positive difference 
of 0.009 in LY gained was to be seen in the empagliflozin 25mg arm with an estimate 
of 4.166 when compared to the sitagliptin 100mg arm with 4.157. Results in the incre-
mental CE ratio (ICER) favored empagliflozin 25mg as a dominant therapy against 
sitagliptin 100mg. Results were sensitive to changes in efficacy inputs and costs; 
probabilistic results were scattered, with a discrete trend towards the cost-saving 
and cost-effective planes. CONCLUSIONS: With a lower cost of treatment at a better 
LY saved level, empagliflozin was estimated to be a cost-saving alternative versus 
sitagliptin when added to MET for patients with T2DM.
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OBJECTIVES: Assess cost-effectiveness of second- and third-line therapies, respec-
tively, in type 2 diabetes, from the Taiwan’s National Health Insurance (NHI) per-
spective. METHODS: Patients, treatment and costs data were gathered from the 
NHI Research Database linked with the National Mortality Registry. There were 
five metformin-dual therapy cohorts: a reference - metformin plus sulphonylureas 
(Met-SU); four comparisons - metformin plus acarbose (Met-ACA), metformin plus 
9.06 QALY. The reason of utility cost was U$1,006.03 and U$2,331.98 respectively. 
According to sensitivity analysis for drug prices (minimum and maximum), NPH 
was considered alternative more cost-effective in all scenarios. Exchange R$2, 67 = 
U$ 1.00 (Jan/15) CONCLUSIONS: Considering the similarity of the results obtained 
from the analysis of effectiveness and utility in comparing Glargine versus NPH 
at MD treatment, it is concluded that the difference remains only in the costs of 
treatment: Glargine costs are higher.
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OBJECTIVES: In Canada, the most commonly utilized oral third-line agent for 
patients with T2DM inadequately controlled on metformin (MET) and a sulfony-
lurea (SU) is sitagliptin (SITA). Canagliflozin (CANA), a novel agent that inhibits 
sodium glucose co-transporter 2 (SGLT2), has demonstrated HbA1c lowering, as 
well as improvements in weight and systolic blood pressure (SBP). The objec-
tive of this analysis was to evaluate the cost-effectiveness of CANA 100 and 300 
mg versus SITA 100 mg in patients inadequately controlled on MET + SU in the 
Canadian setting. METHODS: In accordance with the CADTH guidelines for eco-
nomic evaluations, cost-utility analysis using ECHO-T2DM, a validated economic 
model, was done to simulate lifetime outcomes and costs of using CANA versus 
SITA in the third-line setting. Patient characteristics and treatment effects were 
sourced from a head-to-head study for the comparison of CANA 300 mg to SITA 
100 mg. In the absence of a direct comparison of CANA 100 mg versus SITA 100 
mg, relative treatment effects for this simulation were obtained from an indirect 
comparison via Bayesian network meta-analysis (NMA), with baseline patient 
characteristics sourced from a pooled analysis of two CANA trials (patients on 
background therapy of MET + SU) that contributed to the NMA. ECHO-T2DM was 
populated with Canadian costs and utility estimates relevant to the Canadian pop-
ulation. RESULTS: Using CANA 300 and 100 mg resulted in mean quality-adjusted 
life year (QALY) gains of 0.08 and 0.04, respectively, and lower costs of $2,035 and 
$981, respectively, compared to SITA over 40 years in patients failing to meet gly-
cemic control on MET + SU. Therefore, CANA “dominated” SITA. CONCLUSIONS: 
CANA used as a third-line agent added on to MET + SU background therapy may 
result in better quality of life outcomes and lower costs when compared to SITA 
(the most common third-line agent in Canada).
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OBJECTIVES: The association between rare genetic disorders, hereditary fructose 
intolerance (HFI) or alpha-1 antitrypsin deficiency (A1AT), and type 2 diabetes 
(T2D) has not yet been investigated. Therefore, the objective of this undertaking 
was to evaluate the association between both genetic disorders and T2D using 
four large observational databases and adjust for ascertainment bias. METHODS: 
Patients with a HFI diagnosis (ICD-9: 271.2) or A1AT diagnosis (ICD-9: 273.4) and 
T2D diagnosis (ICD-9: 250.x0 or 250.x2) were identified in the Truven MarketScan 
Claims Database (2007-2012), Optum Claims Database (2002-2012), Humedica 
Electronic Health Records (EHR) Database (2007-2012), and GE Centricity EHR 
Database (1995-2012). The association between both genetic disorders and T2D 
was compared to the association between T2D and seven negative control chronic 
diseases with no established relationship with T2D. RESULTS: The unadjusted 
association between both genetic disorders and T2D was positive and hetero-
geneous (p<0.001) in all four databases. The unadjusted pooled odds ratio (OR) 
calculated using a random-effects model meta-analysis was 3.48 (95% CI: 2.21-
5.46) for HFI and 2.71 for A1AT (95% CI: 1.75-4.20). After pooling all patients and 
adjusting for the negative controls using a random-effects model meta-analysis, 
it was found that HFI patients have a 73% increased odds of T2D (ratio of odds 
ratios [ROR]=1.73, 95% CI: 1.08-2.75) compared to patients with negative control 
diseases; the association was stronger when utilizing a fixed-effects model meta-
analysis (ROR=2.19, 95% CI: 2.07-2.31). The adjusted association between A1AT and 
T2D was statistically significant in the fixed-effects (ROR=1.33, 95% CI: 1.27-1.40) 
model meta-analysis but not the random-effects model meta-analysis (ROR=1.35, 
95% CI: 0.86-2.12). CONCLUSIONS: HFI and T2D were positively associated after 
adjustment for negative control chronic diseases in both meta-analysis models. 
Rare disease researchers using observational data to conduct comorbidity analyses 
can utilize negative controls and multiple datasets to account for ascertainment 
bias and database heterogeneity, respectively.
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OBJECTIVES: To compare the cost-effectiveness of canagliflozin (CANA) and dapagli-
flozin (DAPA), two compounds with sodium glucose co-transporter 2 (SGLT2) activity, 
in dual therapy as add-on to metformin from the Spanish National Health System 
perspective. Network meta-analyses (NMAs) have found that CANA 300 mg lowers 
HbA1c more than DAPA 10 mg in dual and triple therapy. Pharmacokinetic and 
pharmacodynamic differences support these results. Specifically, CANA 300 mg has 
been shown to reduce the renal threshold for glucose excretion more than DAPA 10 
